Moderna Inc is a biotechnology company focused on developing innovative messenger RNA (mRNA) therapeutics and vaccines for a wide array of diseases. Utilizing its proprietary mRNA technology platform, Moderna aims to harness the body's own cellular machinery to produce proteins that can help prevent or treat illnesses, including infectious diseases, cancer, and rare genetic disorders. The company gained significant attention for its development of an effective COVID-19 vaccine, but its pipeline also includes various other candidates in different stages of clinical development aimed at addressing unmet medical needs. Through its research and development efforts, Moderna seeks to transform the field of medicine and improve patient outcomes globally. Read More
Shares of biotechnology company Moderna (NASDAQ:MRNA)
fell 3.5% in the afternoon session after the stock retreated, giving back some of the strong gains from the previous session that were fueled by reports of potential buyout or partnership discussions.
Join us in exploring the top gainers and losers within the S&P500 index one hour before the close of the markets on Friday as we examine the latest happenings in today's session.
San Francisco, CA – October 31, 2025 – Artificial intelligence (AI) is ushering in a transformative era for the pharmaceutical industry, particularly in the often-overlooked yet critical domain of excipient development. These "inactive" ingredients, which constitute the bulk of most drug formulations, are now at the forefront of an AI-driven innovation wave. By leveraging advanced [...]
The pharmaceutical industry is experiencing a profound and immediate transformation as Artificial Intelligence (AI) becomes a strategic imperative for localizing supply chains, fundamentally enhancing both resilience and efficiency through intelligent logistics and regional optimization. This shift, driven by geopolitical concerns, trade tariffs, and the lessons learned from global disruptions like the COVID-19 pandemic, is no [...]
Stay informed about the performance of the S&P500 index in the middle of the day on Friday. Uncover the top gainers and losers in today's session for valuable insights.
The pharmaceutical industry is in the midst of a profound and rapid transformation, driven by the pervasive integration of Artificial Intelligence (AI). What was once a futuristic concept is, by late 2025, an established force, fundamentally reshaping drug development and operational workflows. This shift is not merely incremental but a comprehensive revolution, accelerating Research & [...]
October 30, 2025 – While the broader S&P 500 Healthcare sector navigated a day of mixed to negative performance, a singular beacon of optimism emerged from the biotechnology landscape today as Moderna (NASDAQ: MRNA) witnessed an extraordinary surge in its stock price. Shares of the mRNA vaccine pioneer jumped by
Curious about the top performers within the S&P500 index one hour before the close of the markets on Thursday? Dive into the list of today's session's top gainers and losers for a comprehensive overview.
Stay updated with the movements of the S&P500 index in the middle of the day on Thursday. Discover which stocks are leading as top gainers and losers in today's session.
While the S&P 500 (^GSPC) includes industry leaders, not every stock in the index is a winner.
Some companies are past their prime, weighed down by poor execution, weak financials, or structural headwinds.
Join us in exploring the top gainers and losers within the S&P500 index one hour before the close of the markets on Tuesday as we examine the latest happenings in today's session.
As the closing bell rings on October 27, 2025, the S&P 500 Healthcare sector stands at a critical juncture, exhibiting the nuanced volatility that defines this essential yet complex segment of the market. While specific daily performance metrics remain unreleased, today's trading likely saw the sector reacting to a
New York, NY – October 23, 2025 – Integer Holdings Corporation (NYSE: ITGR), a leading medical device contract manufacturer, experienced a dramatic downturn in its stock performance today, with shares plummeting a staggering 31.4%. The significant sell-off came despite the company reporting strong third-quarter 2025 earnings that largely met or exceeded
CAMBRIDGE, MA / ACCESS Newswire / October 23, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced it was ranked as a top employer in the global biopharmaceutical industry in Science and Science Careers' 2025 Top Employers Survey for the eleventh consecutive year. Moderna was recognized for its commitment to continuous innovation and a culture that reflects the values of its employees.
As we await the opening of the US market on Thursday, let's delve into the pre-market session and discover the S&P500 top gainers and losers shaping the early market sentiment.
CAMBRIDGE, MA / ACCESS Newswire / October 23, 2025 / Moderna, Inc. (Nasdaq:MRNA) today announced that it will host its Investor Event - Analyst Day at 9:00 a.m. ET on Thursday, November 20, 2025.
The biotech will continue testing the vaccine in bone marrow transplant patients, where CMV reactivation can cause serious complications, and said no safety concerns were identified.
Washington D.C., October 22, 2025 – The world stands at a critical juncture as the 2025 Economic Freedom of the World index, prominently released by the Fraser Institute in collaboration with the Cato Institute, reveals an alarming and unprecedented trend: a decline in global economic freedom for four consecutive years.
